Science and Technology
ImmTune is pioneering the development of highly selective, safe and efficient delivery vectors for in-patient generation of cell and gene therapies. Advancements in cell and gene technologies including CRISPR, CAR-T immunotherapies are transforming the way certain fatal illnesses are managed, and cured. However, all the currently approved therapies are manufactured ex vivo, and face several challenges around limited availability, cost, and variable efficiency.
To overcome these challenges, ImmTune is developing a delivery technology, which allows us to safely, and effectively deliver genetic cargoes to targeted cells directly inside patients. This in-body generation of therapeutically active cells is cheaper, and produces more effective and longer-lasting curative products. This allows ImmTune to platform and empower the revolutionary genetic medicines of tomorrow.
ImmTune first product is being developed for CAR-T therapy which is a form of cancer treatment that uses a chimeric antigen receptor (CAR) to target killer T-cells towards tumour cells in the body.
We are building a platform which would allow us to use our technology well beyond blood cancer, and provide an affordable option for other disease indications including solid tumours, autoimmune and infectious diseases.